|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-7-6
|
|
pubmed:abstractText |
T-cell mediated inflammation plays an important role in the aetiology of psoriasis. We describe a case of severe recalcitrant psoriasis responding well to combined cyclosporin and basiliximab (Simulect(R) Novartis Pharmaceuticals UK Ltd), an interleukin-2 receptor (IL-2R; CD25) chimeric monoclonal antibody.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0307-6938
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
195-7
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10844492-Antibodies, Monoclonal,
pubmed-meshheading:10844492-Cyclosporine,
pubmed-meshheading:10844492-Dermatologic Agents,
pubmed-meshheading:10844492-Drug Therapy, Combination,
pubmed-meshheading:10844492-Female,
pubmed-meshheading:10844492-Humans,
pubmed-meshheading:10844492-Immunosuppressive Agents,
pubmed-meshheading:10844492-Middle Aged,
pubmed-meshheading:10844492-Psoriasis,
pubmed-meshheading:10844492-Receptors, Interleukin-2,
pubmed-meshheading:10844492-Recombinant Fusion Proteins,
pubmed-meshheading:10844492-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody.
|
|
pubmed:affiliation |
Department of Dermatology, Royal Lancaster Infirmary, UK. CarolineO@doctors.org.uk
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
